CA2328896A1 - Traitement de trouble anxieux generalise avec de la paroxetine - Google Patents

Traitement de trouble anxieux generalise avec de la paroxetine Download PDF

Info

Publication number
CA2328896A1
CA2328896A1 CA002328896A CA2328896A CA2328896A1 CA 2328896 A1 CA2328896 A1 CA 2328896A1 CA 002328896 A CA002328896 A CA 002328896A CA 2328896 A CA2328896 A CA 2328896A CA 2328896 A1 CA2328896 A1 CA 2328896A1
Authority
CA
Canada
Prior art keywords
paroxetine
treatment
pharmaceutically acceptable
anxiety disorder
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002328896A
Other languages
English (en)
Inventor
Rocco Zaninelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2328896A1 publication Critical patent/CA2328896A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne une méthode de traitement d'un trouble anxieux généralisé, la méthode consistant à administrer une quantité effective non toxique de paroxétine ou son sel ou solvate acceptable du point de vue pharmaceutique à un animal humain ou non humain en présentant le besoin.
CA002328896A 1998-04-22 1999-04-22 Traitement de trouble anxieux generalise avec de la paroxetine Abandoned CA2328896A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9808479.1A GB9808479D0 (en) 1998-04-22 1998-04-22 Method of treatment
GB9808479.1 1998-04-22
PCT/US1999/008786 WO1999053919A1 (fr) 1998-04-22 1999-04-22 Traitement de trouble anxieux generalise avec de la paroxetine

Publications (1)

Publication Number Publication Date
CA2328896A1 true CA2328896A1 (fr) 1999-10-28

Family

ID=10830715

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002328896A Abandoned CA2328896A1 (fr) 1998-04-22 1999-04-22 Traitement de trouble anxieux generalise avec de la paroxetine

Country Status (20)

Country Link
EP (1) EP1073437A4 (fr)
JP (1) JP2002512189A (fr)
KR (1) KR20010034817A (fr)
CN (1) CN1298301A (fr)
AP (1) AP2000001959A0 (fr)
AU (1) AU3864899A (fr)
BG (1) BG104939A (fr)
BR (1) BR9909791A (fr)
CA (1) CA2328896A1 (fr)
CZ (1) CZ20003885A3 (fr)
EA (1) EA200001088A1 (fr)
GB (1) GB9808479D0 (fr)
HU (1) HUP0101350A3 (fr)
ID (1) ID27546A (fr)
IL (1) IL139167A0 (fr)
NO (1) NO20005286L (fr)
PL (1) PL343494A1 (fr)
SK (1) SK15672000A3 (fr)
TR (1) TR200003082T2 (fr)
WO (1) WO1999053919A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2297550B (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
PL343494A1 (en) 2001-08-27
CN1298301A (zh) 2001-06-06
AU3864899A (en) 1999-11-08
JP2002512189A (ja) 2002-04-23
NO20005286L (no) 2000-12-20
HUP0101350A2 (hu) 2002-05-29
TR200003082T2 (tr) 2001-01-22
BG104939A (bg) 2001-09-28
KR20010034817A (ko) 2001-04-25
IL139167A0 (en) 2001-11-25
EP1073437A4 (fr) 2003-04-16
AP2000001959A0 (en) 2000-12-31
HUP0101350A3 (en) 2002-06-28
CZ20003885A3 (cs) 2001-09-12
WO1999053919A1 (fr) 1999-10-28
EP1073437A1 (fr) 2001-02-07
NO20005286D0 (no) 2000-10-20
BR9909791A (pt) 2000-12-26
GB9808479D0 (en) 1998-06-17
ID27546A (id) 2001-04-12
EA200001088A1 (ru) 2001-04-23
SK15672000A3 (sk) 2001-04-09

Similar Documents

Publication Publication Date Title
US5371092A (en) Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
EP0269303B1 (fr) Dérivés du pipéridine pour le traitement de la douleur
EP0323745B1 (fr) Préparations pharmaceutiques
US6121291A (en) Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder
AP460A (en) Naphthyl derivative for treatment method.
AU739466B2 (en) Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI)
JPH06511231A (ja) 2−(ピロリジニル−1−メチル)−ピペリジン誘導体およびκ受容体アゴニストとしてのその使用
CA2328896A1 (fr) Traitement de trouble anxieux generalise avec de la paroxetine
EP0372694A2 (fr) Dérivés azacycliques à activité diurétique
MXPA00010343A (en) Treatment of generalized anxiety disorder with paroxetine
KR20010071893A (ko) 치료 방법
WO1992008451A1 (fr) Utilisation de nabumetone pour le traitement de douleurs associees au cancer
WO1992008452A1 (fr) Utilisation de nabumetone pour le traitement de syndromes de douleurs myofasciales
MXPA00000522A (en) Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (ssri)
ITMI960114A1 (it) Uso di derivati di idroisochinolina

Legal Events

Date Code Title Description
FZDE Discontinued